Skip to main content

Table 4 Multivariate analysis of clinical success for all AG considering targeted Cmax (maximal concentration) attainment

From: An international survey on aminoglycoside practices in critically ill patients: the AMINO III study

  Clinical success
  OR (95% CI) P value
Medical admission 1.08 [0.67; 1.74] 0.74
Male 0.60 [0.32; 1.12] 0.11
Age (years) 1.00 [0.99; 1.02] 0.67
BMI (kg m−2) 1.01 [0.97; 1.04] 0.91
SOFA score 0.85 [0.79; 0.91]  < 0.0001
Serum creatinine (µmoL L−1) 1.00 [0.99; 1.0] 0.52
Empirical treatment 0.71 [0.33; 1.53] 0.39
Bacteremia 0.87 [0.49; 1.55] 0.64
Cmax attainment 1.24 [0.79; 1.94] 0.35
  1. Italic values indicates P values <0.05
  2. OR were calculated with a GEE model assuming an exchangeable correlation structure. P values result of a Wald test. The regression was based on 360 patients. The targeted Cmax was defined as a serum level above 60 mg L−1 for amikacin and 20 mg L−1 for gentamicin and tobramycin
  3. OR: odds ratio; CI: confidence interval, BMI: body mass index, GEE: generalized estimating equations
\